Other News To Note
Friday, January 13, 2012
NovAliX SAS, of Strasbourg, France, is partnering with Teijin Pharma Ltd., of Tokyo, to develop drug candidates against multiple targets across different therapeutic areas. Under the collaboration, NovAliX will use its Graffinity SPR-based screening technology to identify novel chemotypes and then engage its nano-MS technology to further characterize selected small-molecule hit structures.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.